{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:44:55Z","timestamp":1781858695168,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,7,26]],"date-time":"2009-07-26T00:00:00Z","timestamp":1248566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00417-009-1151-1","type":"journal-article","created":{"date-parts":[[2009,7,25]],"date-time":"2009-07-25T15:49:46Z","timestamp":1248536986000},"page":"1635-1641","source":"Crossref","is-referenced-by-count":61,"title":["Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion"],"prefix":"10.1007","volume":"247","author":[{"given":"Alexandra E.","family":"Hoeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B.","family":"Schaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"Scheuerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dithmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,26]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1755-3768.2007.01144.x","volume":"86","author":"N Berker","year":"2008","unstructured":"Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245\u2013252","journal-title":"Acta Ophthalmol"},{"key":"1151_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00347-007-1514-0","volume":"104","author":"AE Hoh","year":"2007","unstructured":"Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 104:290\u2013294","journal-title":"Ophthalmologe"},{"key":"1151_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/112067210501500615","volume":"15","author":"JB Jonas","year":"2005","unstructured":"Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751\u2013758","journal-title":"Eur J Ophthalmol"},{"key":"1151_CR4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.1989.01070020367037","volume":"107","author":"D Klein MLFinkelstein","year":"1989","unstructured":"Klein MLFinkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297\u20131302","journal-title":"Arch Ophthalmol"},{"key":"1151_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","volume":"244","author":"H Noma","year":"2006","unstructured":"Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309\u2013315","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1151_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(98)93020-2","volume":"105","author":"J Pe\u2019er","year":"1998","unstructured":"Pe\u2019er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412\u2013416","journal-title":"Ophthalmology"},{"key":"1151_CR7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00417-008-0866-8","volume":"246","author":"EJ Chung","year":"2008","unstructured":"Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241\u20131247","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1151_CR8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00347-008-1759-2","volume":"105","author":"AE Hoh","year":"2008","unstructured":"Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) OCT-guided reinjection of 2.5\u00a0mg bevacizumab for treating macular edema due to retinal vein occlusion. Ophthalmologe 105:1121\u20131126","journal-title":"Ophthalmologe"},{"key":"1151_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","volume":"92","author":"TC Kreutzer","year":"2008","unstructured":"Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351\u2013355","journal-title":"Br J Ophthalmol"},{"key":"1151_CR10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/IAE.0b013e3180ed458d","volume":"27","author":"SG Priglinger","year":"2007","unstructured":"Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004\u20131012","journal-title":"Retina"},{"key":"1151_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00347-007-1509-x","volume":"104","author":"KB Schaal","year":"2007","unstructured":"Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S (2007) Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 104:285\u2013289","journal-title":"Ophthalmologe"},{"key":"1151_CR12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00417-007-0569-6","volume":"245","author":"A Stahl","year":"2007","unstructured":"Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429\u20131436","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1151_CR13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajo.2008.08.016","volume":"147","author":"RF Spaide","year":"2008","unstructured":"Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2008) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298\u2013306","journal-title":"Am J Ophthalmol"},{"key":"1151_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","volume":"247","author":"GB Jaissle","year":"2009","unstructured":"Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27\u201333","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1151_CR15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","volume":"92","author":"K Kriechbaum","year":"2008","unstructured":"Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518\u2013522","journal-title":"Br J Ophthalmol"},{"key":"1151_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","volume":"27","author":"MD Rabena","year":"2007","unstructured":"Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419\u2013425","journal-title":"Retina"},{"key":"1151_CR17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","volume":"143","author":"SA Pai","year":"2007","unstructured":"Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601\u2013606","journal-title":"Am J Ophthalmol"},{"key":"1151_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","volume":"115","author":"The Central Vein Occlusion Study Group","year":"1997","unstructured":"The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486\u2013491","journal-title":"Arch Ophthalmol"},{"key":"1151_CR19","first-page":"98","volume":"38","author":"Y Zhang HXia","year":"2002","unstructured":"Zhang HXia Y (2002) Analysis of visual prognosis and correlative factors in retinal vein occlusion. Zhonghua Yan Ke Za Zhi 38:98\u2013102","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"1151_CR20","first-page":"293","volume":"110","author":"M Sasahara","year":"2006","unstructured":"Sasahara M, Mikawa A, Tajiri K, Kojima H, Saito I (2006) Visual prognosis of branch retinal vein occlusion with macular edema. Nippon Ganka Gakkai Zasshi 110:293\u2013299","journal-title":"Nippon Ganka Gakkai Zasshi"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1151-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1151-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:48Z","timestamp":1559072448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,26]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1151-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,26]]}}}